{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:25:22Z","timestamp":1788009922178,"version":"build-2784847793"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.msard.2025.106410","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T02:39:06Z","timestamp":1743993546000},"page":"106410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The utility of serum neurofilament light chain in MOGAD: Current insights and future directions"],"prefix":"10.1016","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7079-4331","authenticated-orcid":false,"given":"Mark","family":"Labib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Thebault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald A.","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Rush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"MacLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauruv","family":"Bose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9658-815X","authenticated-orcid":false,"given":"Giulia","family":"Fadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2025.106410_bib0001","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-33158-8","article-title":"Serum GFAP as a biomarker for disease severity in multiple sclerosis","volume":"8","author":"Abdelhak","year":"2018","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.msard.2025.106410_bib0002","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S1474-4422(23)00210-7","article-title":"Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study","volume":"22","author":"Abdelhak","year":"2023","journal-title":"Lancet Neurol."},{"issue":"9","key":"10.1016\/j.msard.2025.106410_bib70","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/jnnp-2022-330412","article-title":"Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder","volume":"94","author":"Aktas","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.msard.2025.106410_bib0004","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"issue":"12","key":"10.1016\/j.msard.2025.106410_bib0005","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1002\/acn3.51234","article-title":"Blood neurofilament light: a critical review of its application to neurologic disease","volume":"7","author":"Barro","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106410_bib0006","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200052","article-title":"Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis","volume":"10","author":"Barro","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.msard.2025.106410_bib0007","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/13524585241226830","article-title":"Effectiveness of immunotherapies in relapsing myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"30","author":"Bilodeau","year":"2024","journal-title":"Mult. Scler. J."},{"issue":"11\u201312","key":"10.1016\/j.msard.2025.106410_bib0008","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1177\/13524585231198751","article-title":"Accuracy of serum neurofilament light to identify contrast-enhancing lesions in multiple sclerosis","volume":"29","author":"Bose","year":"2023","journal-title":"Mult. Scler. J."},{"issue":"12","key":"10.1016\/j.msard.2025.106410_bib0009","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1177\/13524585221097296","article-title":"Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis","volume":"28","author":"Brune","year":"2022","journal-title":"Mult. Scler. J."},{"issue":"12","key":"10.1016\/j.msard.2025.106410_bib0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.37833","article-title":"Frequency of new silent MRI lesions in myelin oligodendrocyte glycoprotein antibody disease and aquaporin-4 antibody neuromyelitis optica spectrum disorder","volume":"4","author":"Camera","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.msard.2025.106410_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.647618","article-title":"Serum neurofilament light and GFAP are associated with disease severity in inflammatory disorders with aquaporin-4 or myelin oligodendrocyte glycoprotein antibodies","volume":"12","author":"Chang","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.msard.2025.106410_bib0012","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12014-024-09466-9","article-title":"The relationship between serum astroglial and neuronal markers and AQP4 and MOG autoantibodies","volume":"21","author":"Chatanaka","year":"2024","journal-title":"Clin. Proteomics"},{"issue":"2","key":"10.1016\/j.msard.2025.106410_bib0013","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1212\/WNL.0000000000009758","article-title":"Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder","volume":"95","author":"Chen","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106410_bib0014","article-title":"Clinical outcomes and prognostic factors in patients with optic neuritis related to NMOSD and MOGAD in distinct ethnic groups from Latin America","volume":"72","author":"Contentti","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106410_bib0015","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3389\/fimmu.2019.00502","article-title":"Cell -Free DNA as a biomarker in autoimmune rheumatic diseases","volume":"10","author":"Duvvuri","year":"2019","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.msard.2025.106410_bib0016","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.25957","article-title":"Silent new brain MRI lesions in children with MOG-antibody associated disease","volume":"89","author":"Fadda","year":"2021","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2025.106410_bib0017","doi-asserted-by":"crossref","first-page":"e425","DOI":"10.1212\/WNL.0000000000207429","article-title":"Deviation from normative whole brain and deep gray matter growth in children with MOGAD, MS, and monophasic seronegative demyelination","volume":"101","author":"Fadda","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106410_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.642384","article-title":"The evolution of neurofilament light chain in multiple sclerosis","volume":"15","author":"Ferreira-Atuesta","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.msard.2025.106410_bib0019","first-page":"101","article-title":"Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management","author":"Freedman","year":"2024","journal-title":"EBioMedicine"},{"issue":"8","key":"10.1016\/j.msard.2025.106410_bib0020","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.msard.2025.106410_bib0021","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/acn3.51355","article-title":"Comparison of SimoaTM and EllaTM to assess serum neurofilament-light chain in multiple sclerosis","volume":"8","author":"Gauthier","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106410_bib0022","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1111\/epi.17132","article-title":"Serum neurofilament light as biomarker of seizure-related neuronal injury in status epilepticus","volume":"63","author":"Giovannini","year":"2022","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.msard.2025.106410_bib0023","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ana.26657","article-title":"Positron emission tomography with [18F]-DPA-714 unveils a smoldering component in most multiple sclerosis lesions which drives disease progression","volume":"94","author":"Hamzaoui","year":"2023","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106410_bib0024","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcad063","article-title":"Early blood neurofilament light chain and myelin oligodendrocyte glycoprotein antibody levels associate with different disease courses of myelin oligodendrocyte glycoprotein-associated disease in children","volume":"5","author":"Horellou","year":"2023","journal-title":"Brain Commun."},{"key":"10.1016\/j.msard.2025.106410_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2023.148587","article-title":"Elevated plasma neurofilament light chain in immune-mediated neurological disorders (IMND) detected by immunomagnetic reduction (IMR)","volume":"1821","author":"Huang","year":"2023","journal-title":"Brain Res."},{"issue":"6","key":"10.1016\/j.msard.2025.106410_bib0026","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1177\/13524585211063756","article-title":"Absence of attack-independent neuroaxonal injury in Mog antibody-associated disease: Longitudinal assessment of Serum Neurofilament Light Chain","volume":"28","author":"Hyun","year":"2022","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106410_bib0027","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.pediatrneurol.2023.07.002","article-title":"Fulminant anti-myelin oligodendrocyte glycoprotein-associated cerebral cortical encephalitis: Case series of a severe pediatric myelin oligodendrocyte glycoprotein antibody-associated disease phenotype","volume":"147","author":"Kannan","year":"2023","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.msard.2025.106410_bib0028","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.neulet.2017.07.050","article-title":"GFAP in early multiple sclerosis: A biomarker for inflammation","volume":"657","author":"Kassubek","year":"2017","journal-title":"Neurosci. Lett."},{"issue":"3","key":"10.1016\/j.msard.2025.106410_bib0029","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000708","article-title":"Serum biomarkers in myelin oligodendrocyte glycoprotein antibody\u2013associated disease","volume":"7","author":"Kim","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.msard.2025.106410_bib0030","doi-asserted-by":"crossref","first-page":"5609","DOI":"10.1038\/s41598-023-32748-5","article-title":"Serum proteins for monitoring and predicting visual function in patients with recent optic neuritis","volume":"13","author":"Kim","year":"2023","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.msard.2025.106410_bib0031","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.yexcr.2004.02.007","article-title":"Epidermal growth factor promotes oligodendrocyte process formation and regrowth after injury","volume":"296","author":"Knapp","year":"2004","journal-title":"Exp. Cell. Res."},{"issue":"13","key":"10.1016\/j.msard.2025.106410_bib0032","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1177\/1352458519885613","article-title":"Neurofilament light levels are associated with long-term outcomes in multiple sclerosis","volume":"26","author":"Kuhle","year":"2020","journal-title":"Mult. Scler. J."},{"issue":"11","key":"10.1016\/j.msard.2025.106410_bib0033","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106410_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.935382","article-title":"Development of a highly sensitive neurofilament light chain assay on an automated immunoassay platform","volume":"13","author":"Lee","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106410_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104100","article-title":"Serum glial fibrillary acidic protein correlates with retinal structural damage in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder","volume":"67","author":"Lin","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2025.106410_bib0036","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jnc.15549","article-title":"Serum neurofilament light chain in adult and pediatric patients with myelin oligodendrocyte glycoprotein antibody-associated disease: correlation with relapses and seizures","volume":"160","author":"Luo","year":"2021","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.msard.2025.106410_bib0037","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/brain\/awaa347","article-title":"Quantitative spinal cord MRI in MOG-antibody disease, neuromyelitis optica and multiple sclerosis","volume":"144","author":"Mariano","year":"2021","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.msard.2025.106410_bib0038","article-title":"Serum neurofilament light chain in NMOSD and related disorders: comparison according to aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies status","volume":"3","author":"Mariotto","year":"2017","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"11","key":"10.1016\/j.msard.2025.106410_bib0039","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1136\/jnnp-2018-320287","article-title":"Neurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders","volume":"90","author":"Mariotto","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106410_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102833","article-title":"NfL levels predominantly increase at disease onset in Mog-ABS-associated disorders","volume":"50","author":"Mariotto","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2025.106410_bib0041","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","article-title":"Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis","volume":"80","author":"Meier","year":"2023","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106410_bib0042","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/13524585211018987","article-title":"Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis","volume":"28","author":"Messina","year":"2022","journal-title":"Mult. Scler. J."},{"issue":"3","key":"10.1016\/j.msard.2025.106410_bib0043","doi-asserted-by":"crossref","first-page":"e1149","DOI":"10.1212\/NXI.0000000000001149","article-title":"Cell-free DNA derived from neutrophils triggers type 1 interferon signature in neuromyelitis optica spectrum disorder","volume":"9","author":"Murata","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106410_bib0044","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.msard.2018.11.026","article-title":"Unique characteristics of optical coherence tomography (OCT) results and visual acuity testing in myelin oligodendrocyte glycoprotein (MOG) antibody positive pediatric patients","volume":"28","author":"Narayan","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106410_bib0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0959-8049(01)00231-3","article-title":"EGFR and cancer prognosis","volume":"37","author":"Nicholson","year":"2001","journal-title":"Eur. J. Cancer"},{"issue":"9","key":"10.1016\/j.msard.2025.106410_bib0046","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0274565","article-title":"Neurofilament light chain in blood as a diagnostic and predictive biomarker for multiple sclerosis: a systematic review and meta-analysis","volume":"17","author":"Ning","year":"2022","journal-title":"PLoS One"},{"issue":"1-2","key":"10.1016\/j.msard.2025.106410_bib0048","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jns.2005.03.015","article-title":"Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss","volume":"233","author":"Petzold","year":"2005","journal-title":"J. Neurol. Sci."},{"issue":"7","key":"10.1016\/j.msard.2025.106410_bib0050","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1001\/jamapediatrics.2013.5316","article-title":"Relationship between the functional status scale and the pediatric overall performance category and pediatric cerebral performance category scales","volume":"168","author":"Pollack","year":"2014","journal-title":"JAMA Pediatr"},{"issue":"2","key":"10.1016\/j.msard.2025.106410_bib0049","doi-asserted-by":"crossref","first-page":"e674","DOI":"10.1212\/NXI.0000000000000674","article-title":"International multicenter examination of MOG antibody assays","volume":"7","author":"Reindl","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"6","key":"10.1016\/j.msard.2025.106410_bib0051","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/acn3.51060","article-title":"Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis","volume":"7","author":"Rosso","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106410_bib0052","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/jon.12826","article-title":"MRI lesion state modulates the relationship between serum neurofilament light and age in multiple sclerosis","volume":"31","author":"Rosso","year":"2021","journal-title":"J. Neuroimaging"},{"issue":"5","key":"10.1016\/j.msard.2025.106410_bib0053","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1191\/1352458502ms845oa","article-title":"The multiple sclerosis functional composite: a new clinical outcome measure for multiple sclerosis trials","volume":"8","author":"Rudick","year":"2002","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106410_bib0054","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.biocel.2014.09.011","article-title":"Relationships between cobalamin, epidermal growth factor, and normal prions in the myelin maintenance of central nervous system","volume":"55","author":"Scalabrino","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.msard.2025.106410_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105729","article-title":"Longitudinal change of serum NfL as disease activity biomarker candidate in MOGAD: a descriptive cohort study","author":"Schindler","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2025.106410_bib0056","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12974-021-02138-7","article-title":"Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder","volume":"18","author":"Schindler","year":"2021","journal-title":"J. Neuroinflammation"},{"issue":"1","key":"10.1016\/j.msard.2025.106410_bib0057","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12974-022-02600-0","article-title":"Impaired response of blood neutrophils to cell-death stimulus differentiates Aqp4-IGG-seropositive NMOSD from MOGAD","volume":"19","author":"Schroeder-Castagno","year":"2022","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.msard.2025.106410_bib0058","first-page":"1108","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management","author":"Sechi","year":"2022","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106410_bib72","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1161\/STROKEAHA.120.031482","article-title":"Serum neurofilament to magnetic resonance imaging lesion area ratio differentiates spinal cord infarction from acute myelitis","volume":"52","author":"Sechi","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.msard.2025.106410_bib0059","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.754518","article-title":"Serum neurofilament light chain levels and myelin oligodendrocyte glycoprotein antibodies in pediatric acquired demyelinating syndromes","volume":"12","author":"Simone","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106410_bib0060","first-page":"1076","article-title":"Reference change values of longitudinal sNfL to detect subclinical disease activity in individual patients with MS","volume":"29","author":"Thebault","year":"2023","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106410_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103535","article-title":"High or increasing serum NfL is predictive of impending multiple sclerosis relapses","volume":"59","author":"Thebault","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2025.106410_bib0062","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1212\/NXI.0000000000000422","article-title":"Neurofilament light chain predicts disease activity in relapsing-remitting MS","volume":"5","author":"Varhaug","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106410_bib0063","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109761","article-title":"Decipher potential biomarkers of diagnosis and disease activity for NMOSD with AQP4 using LC-MS\/MS and simoa","volume":"116","author":"Wang","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.msard.2025.106410_bib0064","article-title":"Serum NfL and EGFR\/NfL ratio mRNAs as biomarkers for phenotype and disease severity of myelin oligodendrocyte glycoprotein IgG-associated disease","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.msard.2025.106410_bib0065","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1177\/13524585221081090","article-title":"Serum neurofilament light-chain levels in children with monophasic myelin oligodendrocyte glycoprotein-associated disease, multiple sclerosis, and other acquired demyelinating syndrome","volume":"28","author":"Wendel","year":"2022","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106410_bib0067","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1007\/s00415-020-10026-y","article-title":"Treatment of MOG antibody associated disorders: results of an international survey","volume":"267","author":"Whittam","year":"2020","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2025.106410_bib0068","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.tins.2015.04.003","article-title":"Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker","volume":"38","author":"Yang","year":"2015","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.msard.2025.106410_bib0069","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104704","article-title":"High serum neurofilament levels are observed close to disease activity events in pediatric-onset MS and MOG antibody-associated diseases","volume":"74","author":"Ziaei","year":"2023","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500152X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500152X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T21:34:37Z","timestamp":1747258477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482500152X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":68,"alternative-id":["S221103482500152X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106410","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The utility of serum neurofilament light chain in MOGAD: Current insights and future directions","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106410","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106410"}}